These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27628785)

  • 1. Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride.
    Wang J; Wu L; Kou L; Xu M; Sun J; Wang Y; Fu Q; Zhang P; He Z
    Int J Pharm; 2016 Nov; 513(1-2):218-226. PubMed ID: 27628785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel self-assembled ES-PLGA hybrid nanoparticles for improving oral absorption of doxorubicin hydrochloride by P-gp inhibition: In vitro and in vivo evaluation.
    Wang J; Li L; Wu L; Sun B; Du Y; Sun J; Wang Y; Fu Q; Zhang P; He Z
    Eur J Pharm Sci; 2017 Mar; 99():185-192. PubMed ID: 27989702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
    Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
    J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
    Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y
    Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance.
    Ke CJ; Chiang WL; Liao ZX; Chen HL; Lai PS; Sun JS; Sung HW
    Biomaterials; 2013 Jan; 34(1):1-10. PubMed ID: 23044041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
    Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
    Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles.
    Tonbul H; Şahin A; Öztürk SC; Ultav G; Tavukçuoğlu E; Akbaş S; Aktaş Y; Esendağlı G; Çapan Y
    J Drug Target; 2024 Nov; 32(9):1101-1110. PubMed ID: 38946465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemosensitization of doxorubicin in multidrug-resistant cells by unimolecular micelles via increased cellular accumulation and apoptosis.
    Wang M; Han M; Li Y; Jin Y; Gao JQ
    J Pharm Pharmacol; 2016 Mar; 68(3):333-41. PubMed ID: 26893058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux.
    Zhang P; Ling G; Sun J; Zhang T; Yuan Y; Sun Y; Wang Z; He Z
    Biomaterials; 2011 Aug; 32(23):5524-33. PubMed ID: 21546082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable Polymersomes as Nanocarriers for Doxorubicin Hydrochloride: Enhanced Cytotoxicity in MCF-7/ADR Cells and Prolonged Blood Circulation.
    Chao Y; Liang Y; Fang G; He H; Yao Q; Xu H; Chen Y; Tang X
    Pharm Res; 2017 Mar; 34(3):610-618. PubMed ID: 28004317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.